BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21280981)

  • 1. Efficacy of plasma TGF-β1 level in predicting therapeutic efficacy and prognosis in patients with advanced non-small cell lung cancer.
    Kumar S; Guleria R; Mohan A; Singh V; Bharti AC; Das BC
    Cancer Invest; 2011 Mar; 29(3):202-7. PubMed ID: 21280981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of plasma tumour necrosis factor-alpha and transforming growth factor-beta1 as predictors of survival and treatment outcome in advanced non-small cell lung carcinoma.
    Kumar S; Guleria R; Mohan A; Singh V; Ali A; Bharti AC; Das BC
    Biomarkers; 2010 Aug; 15(5):446-53. PubMed ID: 20486867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of utility of plasma TNF-alpha level in predicting therapeutic efficacy in patients with advanced non-small cell lung cancer.
    Kumar S; Guleria R; Singh V; Mohan A; Bharti AC; Das BC
    Cytokine; 2010 Sep; 51(3):245-8. PubMed ID: 20599393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung cancer: a combined analysis from Beijing and Michigan.
    Zhao L; Wang L; Ji W; Wang X; Zhu X; Hayman JA; Kalemkerian GP; Yang W; Brenner D; Lawrence TS; Kong FM
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1385-90. PubMed ID: 19231104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer.
    Zhao L; Sheldon K; Chen M; Yin MS; Hayman JA; Kalemkerian GP; Arenberg D; Lyons SE; Curtis JL; Davis M; Cease KB; Brenner D; Anscher MS; Lawrence TS; Kong FM
    Lung Cancer; 2008 Feb; 59(2):232-9. PubMed ID: 17905467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer.
    De Jaeger K; Seppenwoolde Y; Kampinga HH; Boersma LJ; Belderbos JS; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1378-87. PubMed ID: 15050313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma nucleosome levels might predict response to therapy in patients with advanced non-small-cell lung cancer.
    Kumar S; Guleria R; Singh V; Bharti AC; Mohan A; Das BC
    Clin Lung Cancer; 2010 Jan; 11(1):36-44. PubMed ID: 20085866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients.
    Wang S; Han X; Hu X; Wang X; Zhao L; Tang L; Feng Y; Wu D; Sun Y; Shi Y
    Clin Chim Acta; 2014 Mar; 430():63-70. PubMed ID: 24378285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer.
    Jin B; Huang AM; Zhong RB; Han BH
    Chemotherapy; 2010; 56(6):417-23. PubMed ID: 21079400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
    Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
    Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients.
    Novakova-Jiresova A; Van Gameren MM; Coppes RP; Kampinga HH; Groen HJ
    Radiother Oncol; 2004 May; 71(2):183-9. PubMed ID: 15110452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes of circulating transforming growth factor-beta1 level during radiation therapy are correlated with the prognosis of locally advanced non-small cell lung cancer.
    Zhao L; Ji W; Zhang L; Ou G; Feng Q; Zhou Z; Lei M; Yang W; Wang L
    J Thorac Oncol; 2010 Apr; 5(4):521-5. PubMed ID: 20130485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
    Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
    Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer.
    Qian Q; Zhan P; Yu L; Shi Y; Cheng J; Wei S; Wang Q; Song Y
    Clin Lung Cancer; 2011 Mar; 12(2):131-7. PubMed ID: 21550560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
    J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer.
    De Vita F; Orditura M; Auriemma A; Infusino S; Roscigno A; Catalano G
    Oncol Rep; 1998; 5(3):649-52. PubMed ID: 9538169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
    Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
    Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-reactive protein as a monitor of chemotherapy response in advanced non-small cell lung cancer (CML study).
    Srimuninnimit V; Ariyapanya S; Nimmannit A; Wonglaksanapimon S; Akewanlop C; Soparattanapaisarn N
    J Med Assoc Thai; 2012 Feb; 95 Suppl 2():S199-207. PubMed ID: 22574550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of IGF-I and IGF-II in patients with lung cancer during chemotherapy.
    Izycki T; Chyczewska E; Naumnik W; Talalaj J; Panek B; Ossolinska M
    Exp Oncol; 2004 Dec; 26(4):316-9. PubMed ID: 15627066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of treatment efficacy of the second and the third generations of chemoradiotherapy regimens containing platinum on advanced non-small cell lung cancer].
    Wang YM; Guo LJ; Li LS; Li P; Zheng J; Li L
    Ai Zheng; 2005 Dec; 24(12):1514-7. PubMed ID: 16351804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.